Christian Capitini
678
page-template,page-template-full_width,page-template-full_width-php,page,page-id-678,page-child,parent-pageid-320,bridge-core-3.0.2,,vertical_menu_enabled,qode-title-hidden,qode_grid_1300,side_area_uncovered_from_content,qode-theme-ver-28.8,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.9.0,vc_responsive
Capitini_Christian_MD

Discovery Spotlight

Christian Capitini, MD

 

Associate Professor
Department of Pediatrics

 

Adoptive cell therapy for the treatment of pediatric cancers and mitigation of graft versus host disease

We focus on development of cell-based therapies including NK cells and CAR T cells, for immunotherapy of childhood cancers. The laboratory is also developing alternatively activated macrophages to treat complications of hematopoietic stem cell transplant like graft-versus-host-disease and acute radiation syndrome. In the clinic, Dr. Capitini is a site Principal Investigator for CAR T-cell trials for tisagenlecleucel (Kymriah), which was FDA-approved in 2017 for the treatment of relapsed/refractory B cell leukemia.

 

Publications:
https://pubmed.ncbi.nlm.nih.gov/?term=christian%20capitini